药物输送
体内
药品
聚乙二醇
材料科学
活性氧
PEG比率
癌症治疗
癌细胞
纳米技术
纳米颗粒
癌症
体外
渗透(战争)
药理学
癌症研究
生物物理学
化学
医学
生物化学
生物
内科学
经济
生物技术
工程类
运筹学
财务
作者
Xiaoding Xu,Phei Er Saw,Wei Tao,Yujing Li,Xiaoyuan Ji,Sushant Bhasin,Yanlan Liu,Dana Ayyash,Jonathan Rasmussen,Marc Huo,Jinjun Shi,Omid C. Farokhzad
标识
DOI:10.1002/adma.201700141
摘要
The application of nanoparticles (NPs) to drug delivery has led to the development of novel nanotherapeutics for the treatment of various diseases including cancer. However, clinical use of NP-mediated drug delivery has not always translated into improved survival of cancer patients, in part due to the suboptimal properties of NP platforms, such as premature drug leakage during preparation, storage, or blood circulation, lack of active targeting to tumor tissue and cells, and poor tissue penetration. Herein, an innovative reactive oxygen species (ROS)-responsive polyprodrug is reported that can self-assemble into stable NPs with high drug loading. This new NP platform is composed of the following key components: (i) polyprodrug inner core that can respond to ROS for triggered release of intact therapeutic molecules, (ii) polyethylene glycol (PEG) outer shell to prolong blood circulation; and (iii) surface-encoded internalizing RGD (iRGD) to enhance tumor targeting and tissue penetration. These targeted ROS-responsive polyprodrug NPs show significant inhibition of tumor cell growth both in vitro and in vivo.
科研通智能强力驱动
Strongly Powered by AbleSci AI